Alzheimer's breakthrough: Vaccine may be on its way, researchers say

Researchers say they've made a major breakthrough in the effort to develop an Alzheimer's disease vaccine.

A team from Université Laval, CHU de Québec, and pharmaceutical firm GlaxoSmithKline discovered that the molecule monophosphoryl lipid A (MPL) stimulates immune cells in the brain, leading to the breakdown of the senile plaques associated with Alzheimer's, according to a Tuesday statement. The researchers observed an 80% reduction of senile plaques in mice injected once a week for 12 weeks with MPL.

MPL's safety has already been established, leading the researchers to believe it can be used in a vaccine to stimulate the immunity of both diagnosed Alzheimer's patients and those at risk.

The study findings appear in an early online edition of the journal Proceedings of the National Academy of Sciences.

News of the potential vaccine breakthrough comes shortly after a government panel delivered recommendations to the Advisory Council on Alzheimer's Research, and outlined ways to improve long-term care for individuals with dementia. The panel said the Centers for Medicare & Medicaid Services should work with Congress to update Medicare coverage to enable more comprehensive care for those with Alzheimer's or other types of dementia.

More in News

Judge dismisses claims of 'nationwide' Medicare fraud in Omnicare antipsychotics case

Judge dismisses claims of 'nationwide' Medicare fraud in ...

Long-term care pharmacy Omnicare will not face charges that it engaged in "nationwide" Medicare fraud for off-label antipsychotics prescriptions, a federal judge recently ruled. However, the pharmacy still faces more ...

Long-term care providers should follow hospitals in adopting EHRs, government says ...

Healthcare providers have already exceeded the government's 2013 adoption goals for electronic health records, the Department of Health and Human Services announced Wednesday.

Five-day COPD treatment quells flare-ups, reduces side effects, researchers find

Patients with chronic obstructive pulmonary disease flare-ups do better with a shorter round of prednisone, researchers have found.